Sugi Predict

Sugi Predict / Compounds / SCHEMBL532887

SCHEMBL532887

SCHEMBL532887

O=S(=O)(Cl)c1c(F)cccc1F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 8/20 0.50
▸ PKLR P30613 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CES2 O00748 2/20 0.39
▸ CES1 P23141 2/20 0.39
▸ IKBKB O14920 1/20 0.36
▸ SLC40A1 Q9NP59 1/20 0.36
▸ KEAP1 Q14145 1/20 0.36
▸ ALOX15 P16050 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ PTGES2 Q9H7Z7 2/20 0.34
▸ PSIP1 O75475 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537200 0.86 PKM (0.48) PKMPKLRALDH1A1TDP1LMNA
SCHEMBL8409302 0.84 ACHE (0.44) PKMPKLRALDH1A1HSD17B10TDP1
SCHEMBL29764209 0.84 ACHE (0.44) PKMPKLRALDH1A1HSD17B10TDP1
SCHEMBL20560224 0.84 PKM (0.42) PKMPKLRALDH1A1HSD17B10TDP1
SCHEMBL30605862 0.84 PKM (0.42) PKMPKLRALDH1A1HSD17B10TDP1
SCHEMBL19858507 0.84 PKM (0.42) PKMPKLRALDH1A1HSD17B10TDP1
SCHEMBL26112948 0.81 PKM (0.40) PKMPKLRALDH1A1HSD17B10TDP1
SCHEMBL1501184 0.81 SLC22A12 (0.42) PKMPKLRHSD17B10CES1PTGES2
SCHEMBL30586543 0.81 SLC22A12 (0.42) PKMPKLRHSD17B10CES1PTGES2
SCHEMBL24429780 0.80 KAT6A (0.42) PKMPKLRALDH1A1TDP1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119565410-A Seawater desalination reverse osmosis membrane, preparation method and application 湖南澳维膜科技有限公司 2025-03-07 — — CN claimed
CN-109438365-B N- (3- ((4-trifluoromethyl) -2-pyrimidinyl) aminophenyl) -2, 6-difluorobenzenesulfonamide derivative 华南师范大学 2022-04-05 — — CN claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 — — US disclosed
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function Lee Moffitt Cancer Center and Research Institute, Inc. (US) 2026-03-03 — — US disclosed
US-20260001864-A1 COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION NANJING SHUOHUI PHARMATECHNOLOGY CO., LTD (CN) 2026-01-01 — — US disclosed
EP-4661966-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF Type6 Therapeutics, Inc. (US) 2025-12-17 — — EP disclosed
US-12428376-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-12427146-B2 C-terminal SRC kinase inhibitors InventisBio Co., Ltd. (CN) 2025-09-30 — — US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 — — US disclosed
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 — — WO disclosed
US-6136825-A ANTIDEPRESSANTS AND CENTRAL NERVOUS SYSTEM AGENTS KNOLL AKTIENGESELLSCHAFT 2000-10-24 — — US disclosed
EP-0948498-A1 SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY KNOLL AKTIENGESELLSCHAFT (DE) 1999-10-13 — — EP disclosed
WO-1998029411-A1 SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY KNOLL AKTIENGESELLSCHAFT (DE) 1998-07-09 — — WO disclosed
WO-1997046207-A2 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-12-11 — — WO disclosed
EP-0804464-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-11-05 — — EP disclosed
WO-1996018644-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1996-06-20 — — WO disclosed
EP-0419831-A2 Substituted sulfonylaminoazoles BAYER AG (DE) 1991-04-03 — — EP disclosed
US-4218476-A Anti-thrombotic N-alkylthioakylamino benzenesulfonamides AB KABI (SE) 1980-08-19 — — US disclosed
EP-0000826-A1 Diorthosubstituted benzene derivatives, especially for use in a method of therapy, processes for their preparation, and pharmaceutical compositions containing them Kabi AB (SE) 1979-02-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427146-B2 C-terminal SRC kinase inhibitors CSK, SRC, CSNK1G2 PKM 2791/4885PKLR 3053/4885ALDH1A1 4861/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B PKM 3865/4885PKLR 4366/4885ALDH1A1 1864/4885
US-20260001864-A1 COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION SLC10A2, SLC6A11, ABCB11 PKM 1088/4885PKLR 2902/4885ALDH1A1 1595/4885
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function CRBN, CD4, ICOS PKM 4127/4885PKLR 1277/4885ALDH1A1 2373/4885
US-12428376-B2 Therapeutic compounds and compositions PDK1, PDK2, PDK3 PKM 6/4885PKLR 23/4885ALDH1A1 1326/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 PKM 1103/4885PKLR 1142/4885ALDH1A1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.